Bayer’s Kerendia (finerenone) Receives the US FDA’s Approval for New Label Update to Treat Chronic Kidney Disease and Type 2 Diabetes
Shots:
- The US FDA has approved a label update for Kerendia in patients with CKD & T2D. The P-III (FIGARO-DKD & FIDELIO-DKD) trial evaluates Kerendia in 13,000+ patients with CKD associated with T2D. Both trials showed a dual cardiorenal risk reduction
- In (the FIGARO-DKD) trial, 13% reduction in risk of the primary composite EPs from time to the first occurrence of CV death, non-fatal MI, non-fatal stroke, or hospitalization for HF by 13% over a median duration of follow-up of 3.4yrs., 29% risk reduction in hospitalization for HF with a 10% reduction in CV death
- Kerendia was approved in the US in July 2021 to reduce the risk of sustained eGFR decline, end-stage kidney disease, CV death, non-fatal MI & hospitalization for HF, based on (FIDELIO-DKD) trial result
Ref: Busineeswire | Image:Bayer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
